Bacterial proteases and haemostasis dysregulation in the CF lung by Reihill, JA et al.
1 
 
BACTERIAL PROTEASES AND HAEMOSTASIS DYSREGULATION IN THE CF LUNG 
James A. Reihill1, Michelle Moreland1, Gavin E. Jarvis1,2, Andrew McDowell1,3, Gisli G. 
Einarsson3, J. Stuart Elborn3, *S. Lorraine Martin1 
1School of Pharmacy and 3Centre for Infection and Immunity, Queen’s University Belfast, 
Belfast BT9 7BL; 2Department of Physiology, Development and Neuroscience, Selwyn 
College, University of Cambridge CB2 3DY; 3Northern Ireland Centre for Stratified Medicine, 
Ulster University, Londonderry BT47 6SB. 
*Corresponding author: S. Lorraine Martin (l.martin@qub.ac.uk, Tel: 02890 97 5711) 
 
 
Running title:  Bacterial proteases and haemostasis dysregulation in CF 
 
  
  
2 
 
Abstract 
Background: Pathogenic bacteria which chronically colonise the cystic fibrosis (CF) lung 
produce a number of virulence determinants, including distinct proteolytic activities. The 
potential role bacterial proteases play on haemostatic dysregulation within the CF lung is 
however poorly defined, despite haemoptysis being a common complication in CF.  
Methods: The potential impact of known CF pathogens (Pseudomonas aeruginosa and 
Burkholderia cepacia complex spp.) on haemostasis was examined for their ability to 
degrade fibrinogen and dysregulate fibrin clot formation and platelet aggregation.  
Results: Results demonstrate that key CF pathogens growing as a biofilm on mucin exhibit 
considerable fibrinogenolytic activity, resulting in fibrinogen breakdown, impaired clot 
formation, and modulation of platelet aggregation. Human neutrophil elastase may also 
contribute to fibrinogen breakdown and dysregulated clot formation at high concentration.  
Conclusion: Bacterial-derived proteases may play an important role in the dysregulation of 
airway haemostasis, and potentially contribute to episodes of haemoptysis within the CF 
lung.   
Keywords: cystic fibrosis; haemostasis; haemoptysis; coagulation; platelet aggregation; 
Pseudomonas aeruginosa, Burkholderia cenocepacia; Burkholderia multivorans. 
Abbreviations: cystic fibrosis (CF), biofilm-conditioned cell-free broth (BC-CFB) 
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Introduction  
As a major interface between the body and outside world, the lung is continually under threat 
from both internal and external insults which have the potential to damage the extensive 
pulmonary vasculature. When damage does occur a cascade of well-defined coagulation 
proteases enable vascular repair and haemostasis through the aggregation of platelets, 
which are stabilised by the formation of a fibrin mesh that forms a temporary plug (stable 
clot). 
Shortly after birth, CF lungs become colonised by a number of bacterial species; however, 
chronic infection with Pseudomonas aeruginosa is particularly problematic as the bacterium 
employs several strategies to evade the host immune system leading to progressive 
pulmonary decline and increased morbidity (1). Furthermore, the most common Burkholderia 
cepacia complex (BCC) species to infect CF airways in the UK and USA, B. cenocepacia 
and B. multivorans (2), are also strongly associated with a rapid clinical deterioration (3). 
These pathogenic bacteria secrete a range of virulence factors, including proteases that are 
known to interfere with critical host processes (4;5). Haemoptysis is a common complication 
of acute pulmonary exacerbation which typically resolves following antibiotic therapy. In 
some cases, however, the condition can be life-threatening due to airway obstruction and 
haemodynamic instability, with the rate of bleeding the most important factor determining 
mortality (6). Although P. aeruginosa-derived proteases have been shown previously to 
degrade and subsequently affect the activity of fibrinogen (7;8), their clinical relevance, 
particularly in regard to their impact on CF lung haemostasis, is unclear.  
The aim of the present investigation was to examine the effect of CF-relevant bacterial 
proteases (from P. aeruginosa B. multivorans and B. cenocepacia) on fibrinogen 
degradation and the downstream impact on in vitro fibrin clot formation. We also sought to 
determine whether bacterial filtrates modulate platelet aggregation. We hypothesized 
bacterial proteases would interfere with these haemostatic processes.  
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2. Materials and Methods 
2.1. Bacterial strains and culture conditions: The bacterial isolates used in the following 
studies typically cause lung infections in the CF respiratory tract including P. aeruginosa 
(PA0219, BCH10-3, PA0025 and PA0049), and the BCC spp. B. multivorans (C1962, 
C1576, C5393) and B. cenocepacia (ET-12 lineage) (J2315, K56-2, BC7, C5424). The 
isolates were obtained from clinical settings (including a selection of both non-epidemic and 
epidemic strains) and the environment (Table 1).  BCC organisms were grown on MAST 
cepacia selective agar, supplemented with B. cepacia Selectatab (Ticarcillin 100 mg/L, 
Polymyxin B 300,000 units/L) (Mast Diagnostics, Merseyside, UK).  P. aeruginosa isolates 
were grown on Müller-Hinton agar (Oxoid Ltd., Basingstoke, Hampshire, UK). Agar plates 
were incubated aerobically at 37oC until sufficient growth was obtained. 
2.2. Cell-Free Broth Preparation: A single colony was inoculated into 50 ml Tryptone Soya 
Broth (TSB; Oxoid Ltd, UK) supplemented with 0.2% (w/v) sucrose before overnight culture 
at 37oC under mild agitation (100 RPM). The culture was then adjusted ~5x107 CFU/ml and 
an aliquot (200 µl) transferred to wells of a polystyrene 96-well microtitre plate, which had 
previously been coated with 1 mg/ml porcine stomach mucin, Type III (Sigma Aldrich, UK). 
The plates were incubated for 24 hours at 37oC under mild agitation (100 RPM) to allow 
attachment of the cells to the surface of the well. Following incubation, non-adherent cells 
were removed and the wells washed three times with sterile PBS. TSB containing 0.2% (w/v) 
sucrose (200 µl) was added to each well and the plates incubated at 37oC under mild 
agitation for a further 48 hours. Following incubation, culture supernatants were harvested, 
centrifuged for 20 minutes at 12,100 x g before filter sterilisation (0.20 µm pore size; VWR 
International). Bacterial biofilm formation on mucin was validated by a crystal violet binding 
assay (Supplementary Fig. 1) and Congo red staining (Supplementary Fig. 2). The resultant 
biofilm-conditioned cell-free broth (BC-CFB) samples were aliquoted and stored at -20oC for 
further experiments. 
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2.3. Fibrinogen zymography: BC-CFBs (25 μl) were analysed under non-reducing 
conditions using 10% SDS-PAGE gels containing 0.1% (w/v) fibrinogen from human plasma 
(Sigma Aldrich, UK). Following electrophoresis, gels were immersed in a 
renaturation/incubation buffer, 50 mM Tris/HCl, pH 7.5 containing 1 mM CaCl2.H2O, 150 mM 
NaCl and 2.5% (v/v) Triton X-100 (Sigma-Aldrich, UK) for 48 hours at 37oC. Clear bands of 
lysis indicative of protease activity were visualized by staining the gels overnight with 0.1% 
(w/v) Coomassie Brilliant Blue R-250 (Sigma-Aldrich, UK) in acetic acid, isopropanol and 
double distilled water (DDW) (10:25:65).  
2.4. Fibrinogen degradation (SDS-PAGE): Fibrinogen from human plasma (Sigma Aldrich, 
USA) was added to BC-CFB samples at a final concentration of 1 mg/ml. Samples were 
incubated at 37oC for 48 hours, resolved by SDS-PAGE (NUPAGE® Novex 4-12% Bis-Tris 
gels, Invitrogen, USA) and then stained with Coomassie Brilliant Blue R-250. 
2.5. Protease inhibitor studies: BC-CFB samples were pre-incubated for 45 minutes at 
37oC in the presence of each individual inhibitor (as outlined in the results section), prior to 
incubation with fibrinogen (1 mg/ml). Samples were incubated at 37oC for 48 hours then 
subjected to SDS-PAGE.  
2.6. In vitro clotting turbidimetric assay: Fibrin clots were formed in 96-well polystyrene 
microtitre plates by first pre-incubating a mixture of purified human fibrinogen (Sigma Aldrich, 
USA) in Tris-buffered saline (TBS; 50 mM Tris/HCl, pH 7.4, containing 150 mM NaCl) and 
2.5 mM CaCl2 for 10 minutes. Following addition of the relevant BC-CFB or unconditioned 
broth as a mock control, samples were incubated for 48 hours at 37oC. Thrombin from 
human plasma (Sigma Aldrich, USA) was then added to trigger clot formation. Clot turbidity 
(A405) was measured over a period of 1 hour using an EL808 plate reader (Biotek 
Instruments, Winooski, VT, USA). Final reactant concentrations were fibrinogen (2.6 mg/ml), 
2.5 mM CaCl2 and 1 nM thrombin (from human plasma) (Sigma-Aldrich) in a total volume of 
200 µl.  
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2.7. Platelet aggregation assay: Blood was collected from consenting healthy human 
donors (ethical approval was granted by the School of Pharmacy Research Ethics 
Committee, Queen’s University, Belfast), and centrifuged at 240 x g for 15 minutes. The 
platelet-rich plasma (PRP)-containing supernatant was carefully removed and centrifuged 
again at 150 x g for 10 minutes to remove red blood cells (RBC). To obtain washed platelets, 
prostaglandin E1 (final concentration 1 µM) was added to stabilise the RBC-free PRP before 
further centrifugation at 640 x g for 15 minutes. The supernatant containing platelet-poor 
plasma was removed, and the pellet re-suspended in 10 ml of the following modified 
Tyrode's solution: 137 mM NaCl; 11.9 mM NaHCO3; 0.4 mM NaH2PO4; 2.7 mM KCl; 1.1 mM 
MgCl2; 5.6 mM glucose; pH 7.4. The platelet count was adjusted to 200 x 10
6/ml, and the 
platelets allowed to rest at room temperature for at least 1 hour. Prior to use, 1 mM CaCl2 
was added to the platelet-containing suspension. Fibrinogen (at a working concentration of 
10 mg/ml) was added to BC-CFB and incubated for 48 hours at 37oC before adding to 
washed platelets to achieve a final fibrinogen concentration of 0.2 mg/ml. Aggregation 
induced by 6 µM ADP was monitored using two BioData PAP-4 aggregometers (Alpha 
Laboratories, Eastleigh, UK). The assay was performed at 37oC with a sample stir speed of 
1000 RPM. The aggregometer automatically generated values for the final extent of 
aggregation, measured as a percentage of a theoretical maximum represented by platelet 
poor plasma. 
2.8. Statistical analysis: Differences between groups (different species or strains of 
bacteria) were determined by non-parametric Mann-Whitney U-test. A p value of < 0.05 was 
considered significant. Data analysis was performed using Prism 5 for Windows Software 
version 5.00 (GraphPad software Inc, CA, USA). 
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3. Results 
3.1. Bacterial filtrates display fibrinogenolytic activity 
The ability of the bacterial filtrates to degrade fibrinogen (1 mg/ml) was assessed by 
fibrinogen zymography. All four P. aeruginosa strains (PA0219, BCH10-3, PA0025 and 
PA0049) produced a number of fibrinogenolytic activities (Fig. 1A). PA0219 showed a band 
of lysis corresponding to ~55 kDa, in addition to some lesser lower molecular weight 
activities, whereas BCH10-3 had a dominant band at ~100 kDa with additional active 
species ranging from 50-100 kDa. PA0025 and PA0049 also showed several bands of lysis 
between ~40 and 100 kDa, with a major species of ~70 kDa present in both. Of the four B. 
cenocepacia strains (J2315, K56-2, C5424 and BC7), only J2315 displayed substantial 
fibrinogenolytic activity (Fig.1A). Multiple bands of degradation were produced by J2315 at 
the following MWs; ~100 kDa, ~70 kDa, ~55 kDa, ~40 kDa and ~20 kDa. BC7 in contrast 
displayed only a single discernible band with a molecular weight of 100 kDa and some other 
minor, more diffuse activities. B. multivorans strains (C1962, C1576 and C5393) exhibited 
fibrinogenolytic activity to a lesser degree, though faint bands were visible at ~70 kDa, ~55 
kDa, ~40 kDa and ~20 kDa (Fig. 1A).  
3.2 Assessment of protease inhibitors on fibrinogenolytic activity  
Each of the bacterial isolates (J2315, PA0025, BCH10-3, PA0049 and PA0219) that 
displayed high levels of fibrinogenolytic activity (Fig. 1A), were further investigated by 
fibrinogen zymography in the presence or absence of protease inhibitors (Fig. 1B-1F). These 
included serine protease inhibitors developed in-house (9) that irreversibly inactivate trypsin- 
(lanes 3,6), elastase- (lane 4), and chymotrypsin-like (lane 5) proteases. The commercially 
available inhibitors EDTA, phosphoramidon and 1,10 phenanthroline (lanes 7-9, 
respectively) were also used. EDTA is an effective chelator of divalent cations whereas 1,10 
phenanthroline complexes with most metal ions and therefore inhibits metalloproteinases 
that require divalent cations, such as zinc, for activity. Phosphoramidon has been shown to 
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be a potent inhibitor of thermolysin and several other metalloproteinases, but only weakly 
inhibits collagenase and possesses no inhibitory activity against trypsin, papain, 
chymotrypsin or pepsin. In these studies, EDTA attenuated degradation of fibrinogen elicited 
by BC-CFB (J2315, PA0025, BCH10-3 and PA0049 although not PA0219) (Fig. 1B-F) 
indicating that either a protease reliant on divalent metal ions for activity is responsible for 
the degradation of fibrinogen observed with these strains, or that EDTA disrupts the 
quaternary structure of fibrinogen making it a less effective substrate for the enzymes. The 
inhibitor 1,10 phenanthroline reduced fibrinogen degradation caused by PA0025 (Fig. 1C) 
and PA0049 (Fig. 1E). The serine protease inhibitors partially inhibited fibrinogenolytic 
activity from strains PA0025, BCH10-3 and PA0049. For J2315, all of the inhibitors (except 
EDTA) increased the ~40 kDa activity. This suggests that multiple proteases are responsible 
for fibrinogen degradation, possibly as a cascade, and that the inhibitors (except EDTA) act 
selectively. 
3.3 Degradation of the fibrinogen molecule by BC-CFB 
Fibrinogen integrity was investigated by SDS-PAGE analysis after incubation of the molecule 
with BC-CFB samples (Fig 2A-C). Degradation of fibrinogen was evident in the presence of 
each bacterial sample (PA0219, C5393 and J2315), however the profiles varied from that 
elicited by the endogenous regulator thrombin (Fig. 2A). Proteolytic processing of fibrinogen 
by PA0219 was almost completely prevented in the presence of EDTA and 1,10 
phenanthroline (Fig. 2A), with some partial protection offered by the individual serine 
protease inhibitors. In contrast, EDTA provided only limited protection to the fibrinogen 
molecule against degradation by B. multivorans proteases (C5393) (Fig. 2B); in this case the 
 sub-unit of fibrinogen appeared to be more resistant. The most significant degradation of 
fibrinogen was observed in the presence of BC-CFB from the B. cenocepacia isolate J2315. 
These activities were resistant to inhibition by all of the compounds tested, although some 
partial protection was provided by one of the in-house trypsin-like inhibitors and EDTA (Fig. 
2C).  
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3.4. Effect of BC-CFB on in vitro fibrin clot formation  
As BC-CFB degraded fibrinogen we proceeded to determine the impact of bacterial 
proteases on fibrin clot formation using an in vitro turbidimetric clotting assay. The basis of 
this assay involves monitoring the thrombin-mediated conversion of soluble fibrinogen to 
insoluble fibrin which gives rise to a measurable increase in sample turbidity. When 
fibrinogen was pre-treated with each of the BC-CFB samples we found that the ability to 
form clots was markedly reduced in all instances (p<0.05) (Fig. 3A-C). Typical values of clot 
formation for BC-CFB treated samples were less than 20% of the thrombin-native fibrinogen 
control (Fig. 3A-C), except for the B. cenocepacia strain BC7 which was slightly higher 
(~30% of control) (Fig. 3B). We observed no difference in the rate of clotting between P. 
aeruginosa, B. cenocepacia and B. multivorans when we performed a sub-analysis (Fig. 
3D).   
3.4 Evaluation of neutrophil elastase on in vitro fibrin clot formation 
Neutrophil elastase (NE) is a key host-derived protease found at significant levels in CF 
airways. Co-incubation experiments demonstrated fibrinogen degradation at NE 
concentrations of 1 μg/ml, but not lower levels (0.1-0.5 μg/ml) (Fig. 4A).  Consistent with this 
observation, significantly impaired thrombin-induced in vitro clotting was observed after 
fibrinogen was incubated with NE at 1 μg/ml (p<0.05), but remained unaffected at the lower 
range of 0.1-0.5 μg/ml (Fig. 4B). 
3.5 Effect of BC-CFB on platelet aggregation   
Platelet aggregation, a key component of haemostasis, requires the binding of fibrinogen 
with activated integrin IIb3 to provide critical cross-links that serve to stabilise the clot. 
Platelet aggregation was assayed using washed platelets collected from human donors to 
determine if BC-CFB samples had any effect on this process. The majority of bacterial 
strains examined reduced the extent of platelet aggregation in comparison to the control. In 
particular, the P. aeruginosa strain PA0219, B. multivorans strain C5393 and B. cenocepacia 
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strains J2315 and BC7 resulted in complete impairment of this process (p<0.05) (Fig 5A-C). 
A number of strains (PA0025, BCH10-3, and K56-2) elicited a modest inhibitory effect on 
platelet aggregation, whereas C1962 and PA0049 had no effect (Fig. 5A-C). The B. 
multivorans strains produced a variable response (Fig. 5D) with C1576 causing an increase 
in platelet aggregation (p=0.076) (Fig. 5B).   
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4. Discussion  
Using a mucin-based biofilm assay to better mimic the environment of the CF lung, we have 
demonstrated in vitro that CF-relevant bacterial proteases have the potential to dysregulate 
haemostasis via the breakdown of fibrinogen, thus contributing to significant impairment of 
fibrin clot formation and platelet aggregation. Our study indicates that multiple bacterial 
proteases, the precise identification of which remains unknown, are involved in the observed 
degradation of fibrinogen.  
Fibrinogen is a soluble, rod-like 340 kDa plasma glycoprotein composed of three pairs of 
polypeptides (two A, two B and two ) linked together by a number of disulphide bridges. 
During the process of coagulation the N-terminal ends of the A and B peptides are 
cleaved by the catalytic action of thrombin to produce insoluble fibrin monomers which then 
polymerise to form a three dimensional network of fibres, the fibrin clot.  Plasma fibrinogen 
concentrations range from 2-4 g /L under physiological conditions however it is often 
elevated (by several fold) in diseases with an inflammatory component, including CF (10-13)  
Extracellular proteases from P. aeruginosa, the major CF lung pathogen, have previously 
been shown to degrade fibrinogen (7). Here we confirm proteases secreted from CF-relevant 
bacteria (P. aeruginosa, B. cenocepacia and B. multivorans) possess considerable 
fibrinogenolytic activity, causing degradation of the fibrinogen molecule and significantly 
reduced in vitro fibrin clot formation. For some isolates, e.g. the B. cenocepacia isolate 
J2315 (14;15), very high levels of fibrinogenolytic activity were observed which correlated 
with complete fibrin degradation and abrogation of in vitro clot formation. J2315 is a strain of 
the ET12 lineage, and the index strain for transmission of this lineage among CF patients in 
the UK and Canada in the 1990s. Interestingly, ‘cepacia syndrome’, a progressive 
pneumonic illness often associated with ET-12 infection, as well as other BCC species, 
results in a rapid decline in CF lung function that is often fatal (3). While the development of 
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haemoptysis is a common feature of ‘cepacia syndrome’, no direct link has yet been 
established.  
In addition to dysregulation of haemostasis, degradation of fibrinogen may also contribute to 
the chronic inflammatory cycle within the CF lung since fibrinogen products are known to act 
as a potent chemotactic agent for leukocytes, including neutrophils (16;17), and can induce 
fibroblast proliferation (18). Interestingly, leucocytosis is a clinical characteristic of ‘cepacia 
syndrome’ (19). Furthermore, the CF lung itself may represent a potential source of 
fibrinogen as alveolar cells have been shown to secrete the molecule when stimulated with 
IL-6, a pro-inflammatory cytokine elevated in CF airways (20). Further work is warranted to 
better understand the wider role of fibrinogen degradation products and their role in the CF 
lung.  
Leukocyte proteases including neutrophil elastase, a key enzyme associated with CF 
pulmonary pathophysiology (21), have been long documented as able to degrade fibrinogen 
(22;23). Interestingly, high levels of neutrophil elastase (1 μg/ml) were necessary to degrade 
fibrinogen and impair clotting, whereas lower concentrations (<0.5 μg/ml) had no effect (Fig. 
4). Whilst it is possible to achieve elastase levels (g) in the CF lung which could start to 
impact on the coagulation process, these studies have shown that considerably lower 
concentrations of bacterial proteases (as present in our BC-CFB preparations) can impair 
clotting. Our data therefore indicates that host and/or bacterial proteases may feasibly 
contribute to a haemoptyic event. Additional work is, however, necessary to better 
understand their individual contributions.  
Platelet aggregation is the process by which platelets adhere to each other at the site of 
injury and form a primary haemostatic plug, which is further stabilised by the conversion of 
fibrinogen to fibrin. A functional platelet assay was used to assess whether bacterial samples 
affect platelet aggregation. Fibrinogen degradation products have been shown previously to 
modulate (both inhibit and accelerate) platelet aggregation (24). We found 5/11 bacterial 
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samples abrogated aggregation (PA0219, C5393, J2315, BC7 and C5424), 4/11 elicited a 
more modest inhibitory effect (PA0025, BCH10-3, and K56-2) whereas 2/11 (C1576 and 
PA0049) did not modulate platelet aggregation. Interestingly, one bacterial isolate C1576 
actually enhanced platelet aggregation. At present it remains unclear as to the underlying 
reasons for this variable impact of BC-CFB on platelet aggregation, but factors other than 
protease activity may be responsible. As well as playing a key role in haemostasis, platelets 
play a major role in inflammation and asthma (25) and platelet abnormalities are apparent in 
CF patients who display thrombocytosis (26), increased platelet reactivity and increased 
secretion of mediators that may negatively impact the lung (27;28). An inverse relationship 
between platelet aggregation and pulmonary function has also been reported (29;30). It 
would be of particular interest to examine the impact of BC-CFB on platelets isolated from 
CF patients and to further determine the downstream impact on platelet-derived 
inflammatory mediators.  
Haemoptysis is a common complication in CF. Although often minor in nature, with slight 
streaking of mucus, massive haemoptysis (defined as acute bleeding >240 ml/ 24h, or 
recurrent bleeding >100 ml/d over several days) (31) occurs in 4.1% of patients and is 
associated with a significant deterioration in lung function over the following year and a 
higher rate of mortality (32). Massive haemoptysis is more prevalent in older patients with 
more advanced disease and represents a growing problem particularly given the continued 
improvement in life expectancy (33;34). The pathogenesis of haemoptysis is not very well 
understood, but is attributed to infection and inflammation-driven changes in the pulmonary 
vasculature, including weakened bronchial arteries and abnormal new vessel formation 
(angiogenesis) which are susceptible to bleeds into the airway lumen during acute infection 
(33;35). Our results showing that CF-relevant bacterial proteases negatively impact key 
haemostatic processes suggest these enzymes may play a role in the excessive 
haemorrhagic tissue damage seen in the later stages of CF lung disease.  
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Overall we have demonstrated that CF-related pathogens have the ability when grown as 
biofilms to secrete a number of proteases that collectively degrade fibrinogen, and prevent 
normal clot formation upon the addition of thrombin. We further demonstrate that the majority 
of BC-CFBs investigated resulted in impaired platelet aggregation. These findings are 
important as platelet aggregation and fibrin clot formation are critical components of 
haemostasis, and may therefore be of significance in the context of haemoptytic events 
observed in CF lung disease. 
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Fig. 1. Fibrinogen zymography of BC-CFB. Fibrinogen degradation was investigated by 
incorporating fibrinogen (1 mg/ml) into the gel matrix prior to polymerisation of the gel. The sample 
profiling was carried out by SDS-PAGE, followed by Coomassie Blue staining.  (A) BC-CFB (10 μl) 
was added to each lane. Lanes were as follows: molecular weight marker; TSB control (lane 1), 
PA0219 (lane 2), BCH10-3 (lane 3), PA0025 (lane 4), PA0049 (lane 5), J2315 (lane 6), K56-2 (lane 
7), C5424 (lane 8), BC7 (lane 9), C1962 (lane 10), C1576 (lane 11) and C5393 (lane 12). (B-E) BC-
CFB samples that displayed considerable fibrinogenolytic activity (B: J2315, C: PA0025, D: BCH10-3, 
E: PA0049, and F: PA0219) were then analysed in the presence of protease inhibitors.  Lanes were 
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as follows: pre-stained protein markers; negative broth control (lane 1); positive bacteria-only control 
(lane 2); bacteria/inhibitor samples: trypsin inhibitor (lane 3); elastase inhibitor (lane 4) chymotrypsin 
inhibitor (lane 5); trypsin inhibitor (lane 6); EDTA (lane 7); phosphoramidon (lane 8) and 1,10-
phenanthroline (lane 9).  DDW control (lane 10). 
 
Fig. 2. Degradation of fibrinogen by BC-CFB with and without protease inhibitors.  Fibrinogen (1 
mg/ml) degradation was investigated by co-incubation with BC-CFB at 37°C for 48 hours with or 
without a pre-incubation step with protease inhibitors (45 minutes, 37°C). Samples were subjected to 
SDS-PAGE followed by Coomassie blue staining.  Representative gels for (A) PA0219; (B) C5393 
and (C) J2315 are shown.  Each lane was as follows: 5 μg fibrinogen (lane 1), fibrinogen and 
thrombin (5 µg and 10 U, respectively) (lane 2), fibrinogen pre-incubated with BC-CFB (lane 3), 
fibrinogen/BC-CFB samples in the presence of in-house (QUB) protease inhibitors (lane 4: trypsin 
inhibitor; lane 5: chymotrypsin inhibitor; lane 6: elastase inhibitor; lane 7: trypsin inhibitor); 
fibrinogen/BC-CFB samples in the presence of commercially available protease inhibitors: EDTA 
(lane 8); phosphoramidon (lane 9); and 1,10-phenanthroline (lane 10).  (Representative figure of n=3 
experiments). 
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Fig. 3. BC-CFB impairs in vitro fibrin clot formation. Clot formation initiated by the addition of 1 nM 
thrombin determined in reactions containing fibrinogen that had undergone previous proteolytic 
processing by bacterial filtrates. Data shown in (A-C) are kinetic traces representative of the values 
obtained from three independent experiments for clot formation in the presence of (A) P. aeruginosa 
(B) B. cenocepacia and (C) B. multivorans isolates. The rate of clot formation was calculated for each 
individual isolate and expressed as a percentage of the thrombin/native fibrinogen control and the 
mean value plotted according to species group (D). 
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Fig. 4. The impact of neutrophil elastase (NE) on fibrinogen status and in vitro fibrin clot 
formation.  (A) Fibrinogen (2.6 mg/ml) degradation was investigated after incubation with various 
doses of recombinant neutrophil elastase at 37
o
C for 48 hours. Samples were then subjected to SDS-
PAGE followed by Coomassie blue staining.  (B) Clot formation measured as a % thrombin control 
(no NE) when NE-fibrinogen samples (200 μl) were spiked with 1 nM thrombin to induce clotting 
(n=4).  
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Fig. 5. Assessment of the ability of washed platelets to undergo aggregation in the presence of 
bacterial-processed fibrinogen. Fibrinogen was incubated with BC-CFB from isolates of (A) P. 
aeruginosa, (B) B. multivorans and (C) B. cenocepacia for 48 hours at 37
o
C then added to washed 
platelets at a final fibrinogen concentration of 0.2 mg/ml. Platelet aggregation was measured upon the 
addition of 6 µM ADP. Results displayed are representative of the values obtained from three 
independent experiments. Platelet aggregation (%) after 360 seconds was plotted according to 
species and shown in (D). 
 
 
 
 
